delpacibart braxlosiran

all catalysts(0)

nothing on the calendar yet

News(4)

• Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test
  The phase 3 Harbor trial of Novartis’ del-desiran has missed its primary endpoint, dealing a major blow to an asset that the Swiss drugmaker acquired in the $12 billion takeover of Avidity Bioscien…
  fiercebiotech · 25d ago
• Epicrispr raises $90M to rewrite treatment of rare muscle disease
  Epicrispr Biotechnologies has raised $90 million in a series C round backed by investors including Sanofi Ventures, positioning the biotech to advance a pipeline of epigenetic medicines led by an e…
  fiercebiotech · 1mo ago
• 4 potential biotech M&A targets, plus a pretty sure bet from J&J
  Pharma is definitely interested in making more deals. But what biotechs will come under the magnifying glass? BioSpace takes a look at companies that analysts see as near-term targets for buyouts.
  biospace · 1mo ago
• Novartis RNA drug acquired in $12B Avidity deal notches a trial win
  The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.
  biopharma_dive · 3mo ago